Member Info for rebarm

Hardly surprising! An RNS is supposed to deliver fresh news. Content of today’s RNS already widely known and priced in. Disappointing and pointless exercise

Keep up xxxA!!

Agree with Dr A on this one

Logical structure ex UK is PHE innovator, licensor and, possibly, maintenance HUI technical sales covering whatever geography in which they have bandwidth. Today they are too small to consider anything else. Linde, assuming contract closure with HUI, deployment and operation. They have the scale and extensive experience.

The revenue comes from license and maintenance fees and at a much lower overhead to PHE.

The UK with Peel? A testbed and showcase!!

Spot on Elrico

Incorrect! AxisBiotix-Ps is a supplement, not a drug, and as such will only alleviate symptoms. Don't get me wrong though, as based on the recent study, it will undoubtedly benefit the lives of many psoriasis sufferers.

https://www.sciencedaily.com/releases/2021/10/211004104229.htm

Jam, try this for starters.
https://www.gov.uk/guidance/negligible-value-agreements#negligible-value-agreement-list-index
There is an NVA list but no sign of mtfb!

Well put Skid. However, I'm sure you will agree that it's about time SOH delivered!

Belgrano, fascinating!

From your post of 07:40, 'the US psoriasis association has been running adverts for AxisBiotix on their website, referring to sbtx as “partners.”' and referenced by you at 08:14.

Since when did you have to pay a subscription to see an advertisement and other campaign related material on an open website?

Belgrano, can you provide links to the US campaigns you reference in this morning's posts? Thanks

Malachi, worth checking out LedZep's excellent post from yesterday, 20:50. I suspect that the planning process in the UK is significantly more rigorous and, as a consequence, more time consuming than in Poland. Furthermore, there are additional demands, such as centrally controlled heating, that will encourage speedier deployment in Poland plus external funding.

Also factor in that whilst PHE's UK partner Peel has much experience in waste management it does not have any practical experience, yet, of building and running a facility such as Protos. A steep learning curve for them. HUI on the other hand has engaged/partnered with companies with significant experience that will undoubtedly facilitate a faster roll-out.

Should PHE have partnered elsewhere? We'll get there, albeit slower than we would have liked!

Bigun2, I don't disagree with you and, yes, it's all in the RNS but my point is AIM is a lottery and if investors/traders can't stand the heat they should get out the f****** kitchen. You win some and you lose some. MTFB a defo loser for small punters and big risk that scenario will not change with the proposed rto!

On Thursday of this week every MTFB shareholder, both LTHs and trading community, had nothing to look forward to and had effectively lost everything. Investing in the biotech start-up sector is high risk, you took that risk and as of Tuesday had lost the lot. Reasons why are irrelevant - you'd done your brains!

Yesterday a lifeline was thrown with some return offered albeit derisory. Most people wont cover there losses but that was the risk you took. Be grateful for small (very!!) mercies but accept and move on and consider the potential.
Despite the negativity, nobody actually knows what the sp will look like next month. Furthermore, nobody actually knows what the prospects are for BiVictriX. It could be a great opportunity for investors or potentially another damp squib like MTFB. You took the risk and so you continue with that risk!
As for warrants, to the multiple moaners claiming they know nothing about them get off your backsides and do some homework. It's not a complex subject and only requires some basic due diligence. They could be good but equally could be worthless. You took the risk!
As for not voting for this offer, please don't for one minute think you are of any relevance to this deal. It will happen whether you like it or not so do try and look on the positive side, look to the future and a potential good opportunity.

PJT12. There is no specific reference to AGL in this article. Focus is on Illumina's sequencing capability for genetic cancer screening.

The technology they use for isolating DNA in blood samples is from Grail. Illumina trying to
re-aquire but a deal is not a foregone conclusion. Grail's isolating capabilities are not close to those of AGL.

Imagination in overdrive here but Illumina's biggest shareholder is Baillie Gifford Health Innovation, the UK fund manager. What do they know about AGL?

Probably not wise to come out with your typically disparaging comments when you have no idea about a poster's background. You really can't stand it when somebody posts something that may offend your view of the world, can you?

You're absolutely correct about the breakdown in relations between the CCP and the democratic world and, in my opinion, they should breakdown further. However, given the close relationship that your friends at Pierce supposedly have with the CCP and their business acumen then one would have thought that would have been factored into their discussions with Opti. Unless of course it is nothing more a convenient excuse for the lack of news?!

For your information, I suspect that I have been invested here for as long as you and probably have a significantly bigger investment. Despite the ongoing sp stagnation, I am a LTH and will remain so because I believe in the science and am confident that sooner or later the market will recognise the significance of what Opti is trying to achieve. However, like many other investors, I am now sick of the constant carrot dangling by SOH assisted by know-it-alls like your good self.

Perhaps time for OptiBiotix to change its name to Opti Manana!!

Correct, but if your research is so superficial that it goes no further than the title of a post then it’s hardly surprising that you missed the content and context. Specsavers should be open tomorrow!!

Actually Aquae, I think it's you that should be at the head of the queue for an appointment at Specsavers! The post from Bubs49 was sepcifically about the RNS May 5th 2020 regarding Pierce Group and lack of deal announcements subsequently. You've posted a very impressive list of deals signed since then not one of which reference Pierce.

I'm sure that given his role with Pierce that if any significant deals had been done then he would have been shouting from the rooftops but strange silence!!

Perhaps you could enlighten us all.

Bubs49.
Suggest you ask Elrico who has a vested interest in Pierce's success. He was punting aggressively when the agreement with Opti was announced last year but, unless too small to warrant an RNS, nothing appears to have happened.

Check out his blog under 'Elrico & Pierce ESIM Disclosure'. Apparently he has a 1% interest in Pierce!!

In all probability, Pierce is another Tata, albeit significantly smaller.

Suspect the pre-launch registration is for two reasons:
- gauge early demand for planning and production
- launch pre-reg number for inclusion in RNS assuming a positive outcome for the AxisBiotix-Ps study. Given timescales until product availability then I'm confident the market would react very positively

Our CEO is a shrewdie!

Suspect he's trying to show how smart he is at not spending a lot of cash on professional research and communications. I've never come across 'ant-man' whoever he might be and, like TW and Elric, no doubt a decent individual but still a cheap/easy comms channel which, unsurprisingly, is unlikely to reach a wide audience of potential investors and, in particular, IIs. Why is he not using Cenkos to put out a formal update? That's what they're paid for and SOH should be taking advantage of their professional reputation, experience and reach.

Whilst as a LTH I am of the opinion that SOH has done, and continues to do, an excellent job there is one major characteristic which I feel is holding the company and, consequently, the share price back. An overbearing arrogance! Those that have met him will, I'm sure, concur.